SAB: NIH Discontinuing Phase 3 for Treatment of COVID-19 Due to Declining COVID Hospitalizations

 

• NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable
• SAB-185 had advanced into Phase 3 after meeting pre-specified efficacy and safety criteria
• SAB-185’s targeted, highly potent, fully human polyclonal antibodies have demonstrated neutralization of multiple SARS-CoV-2 variants in vitro, including Delta and Omicron
• SAB is evaluating future clinical plans for SAB-185 including potential targeted applications such as prophylaxis and treatment in high-risk patient groups

https://www.biospace.com/article/releases/sab-biotherapeutics-reports-nih-is-discontinuing-phase-3-activ-2-trial-assessing-sab-185-for-treatment-of-covid-19-due-to-declining-covid-hospitalizations/